n = 22 | Mean ± S.D. | Median | Range | |
---|---|---|---|---|
Age (year) | 66.09 ± 7.78 | 65 | 51–80 | |
Sex | ||||
Male | 17 | |||
Female | 5 | |||
Body Height (cm) | 162.84 ± 8.35 | 163.35 | 149.00–175.30 | |
Body Weight (kg) | 58.14 ± 9.11 | 56.55 | 40.00–74.00 | |
PS | ||||
0 | 14 | |||
1 | 6 | |||
2< | 2 | |||
Type of cancer | ||||
Colon | 13 | |||
Rectal | 7 | |||
Cecum | 2 | |||
EGFR-targeting antibodies | ||||
Cetuximab | 14 | |||
Panitumumab | 8 | |||
No metastatic sites | ||||
One | 7 | |||
Two | 8 | |||
Three or more | 7 | |||
Involved sites | 6 | |||
Lung | 13 | |||
Liver | 14 | |||
Lymph nodes | 3 | |||
Bone | 0 | |||
Peritoneal | 7 | |||
Median treatment cycle | 9.30 | 1.00–23.00 | ||
Median treatment duration, weeks | 9.00 | 2.00–46.00 | ||
Combination of Magnesium oxide formulation | ||||
Yes | 11 | |||
No | 11 | |||
Combination regimen | ||||
FOLFIRI base | 15 | |||
FOLFOX base | 2 | |||
CPT-11 | 2 | |||
Monotherapy | 3 | |||
Serum Magnesium (mg/dL) | 2.13 ± 0.22 | 2.00 | 1.80–2.60 | |
Serum Calcium (mg/dL) | 9.96 ± 0.33 | 9.85 | 9.50–10.50 | |
Laboratory data | ||||
Neu (/mm3) | 3716.8 ± 1459.1 | 3475.0 | 1380.0–6880.0 | |
WBC (/mm3) | 5936.3 ± 1685.9 | 5450.0 | 3200.0–10100.0 | |
PLT (/mm3) | 207,091 ± 5651 | 205,500 | 111,000–330,000 | |
Hb (g/dl) | 11.67 ± 1.73 | 11.55 | 7.80–14.4 | |
sCre (mg/dl) | 0.73 ± 0.31 | 0.64 | 0.51–1.88 | |
AST (IU/l) | 20.40 ± 4.44 | 21.00 | 12.00–28.00 | |
ALT (IU/l) | 15.40 ± 7.08 | 13.50 | 5.00–30.00 |